Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).

Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG.

JAMA. 1993 Nov 24;270(20):2451-5.

PMID:
8230622
3.

Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.

Bigger JT Jr, Rolnitzky LM, Steinman RC, Fleiss JL.

J Am Coll Cardiol. 1994 Mar 1;23(3):733-40.

5.

The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.

Kellen JC, Ettinger A, Todd L, Brezsnyak ML, Campion J, McBride R, Thomas S, Corum J, Schron E.

Am J Crit Care. 1996 Jan;5(1):19-25.

PMID:
8680488
6.

Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.

Epstein AE, Bigger JT Jr, Wyse DG, Romhilt DW, Reynolds-Haertle RA, Hallstrom AP.

J Am Coll Cardiol. 1991 Jul;18(1):14-9. Erratum in: J Am Coll Cardiol 1991 Sep;18(3):888.

PMID:
1904891
8.

The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.

Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW.

J Am Coll Cardiol. 1992 Apr;19(5):894-8.

9.
10.

Association between ease of suppression of ventricular arrhythmia and survival.

Goldstein S, Brooks MM, Ledingham R, Kennedy HL, Epstein AE, Pawitan Y, Bigger JT.

Circulation. 1995 Jan 1;91(1):79-83.

11.

Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).

Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL.

J Am Coll Cardiol. 1994 Feb;23(2):283-9.

PMID:
8294678
12.

Treatment of ventricular arrhythmias after CAST.

Tonkin AM.

Med J Aust. 1992 Apr 6;156(7):488-92. Review.

PMID:
1372950
13.

The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.

Pratt CM, Moye LA.

Am J Cardiol. 1990 Jan 16;65(4):20B-29B. Review.

PMID:
2105049
14.

Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.

Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, Friedman L, Keller M, Josephson RA.

J Am Geriatr Soc. 1992 Jul;40(7):666-72.

PMID:
1607582
15.

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al.

N Engl J Med. 1991 Mar 21;324(12):781-8.

16.

Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.

Bigger JT Jr.

Am J Cardiol. 1990 Feb 20;65(8):3D-10D; discussion 68D-71D.

PMID:
2106253
17.

Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.

Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K, Morganroth J, Schlant RC, Waldo AL.

J Am Coll Cardiol. 1991 Nov 15;18(6):1434-8.

PMID:
1939943
18.

Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.

Wyse DG, Hallstrom A, McBride R, Cohen JD, Steinberg JS, Mahmarian J.

J Am Coll Cardiol. 1991 Jul;18(1):20-8.

PMID:
1904892
19.
20.

A critical appraisal of the cardiac arrhythmia suppression trial (CAST).

Naccarelli GV, Dougherty AH, Wolbrette D, Wiggins S.

Appl Cardiopulm Pathophysiol. 1991;4(1):9-16.

PMID:
10147539
Items per page

Supplemental Content

Write to the Help Desk